Globus Medical, Inc. $GMED Shares Purchased by Sculptor Capital LP

Sculptor Capital LP raised its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 1.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,058,000 shares of the medical device company’s stock after acquiring an additional 58,000 shares during the quarter. Globus Medical makes up approximately 2.8% of Sculptor Capital LP’s holdings, making the stock its 6th biggest position. Sculptor Capital LP’s holdings in Globus Medical were worth $263,477,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Sanctuary Advisors LLC boosted its holdings in Globus Medical by 2.3% during the first quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock worth $570,000 after purchasing an additional 151 shares during the last quarter. SBI Securities Co. Ltd. grew its position in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. Parallel Advisors LLC grew its position in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. Finally, Allworth Financial LP increased its stake in Globus Medical by 1.6% in the 4th quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock valued at $1,095,000 after buying an additional 199 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GMED. Wells Fargo & Company reduced their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus lowered their target price on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research report on Wednesday, July 8th. Needham & Company LLC lifted their target price on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $103.75.

Globus Medical Trading Down 0.0%

Shares of GMED opened at $76.46 on Monday. The company’s fifty day simple moving average is $79.79 and its 200 day simple moving average is $86.03. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The company has a market cap of $10.38 billion, a price-to-earnings ratio of 17.78, a PEG ratio of 1.58 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. During the same quarter last year, the company posted $0.68 earnings per share. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insider Activity

In other news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 18.38% of the company’s stock.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.